中国药物经济学Issue(2)：7-10,4.DOI:10.12010/j.issn.1673-5846.2016.02.001
转移性结直肠癌二线化疗方案的成本-效果分析
Cost-Effectivness Analysis of Second-Line Chemotherapy Therapies For Metastatic Colorectal Cancer
边申溦 1刘跃华 1刘国恩1
作者信息
- 1. 北京大学中国卫生经济研究中心，北京 100871
- 折叠
摘要
Abstract
Objective The purpose of this study was to conduct a cost-effectiveness analysis of second-line chem- otherapy therapies for metastatic colorectal cancer(mCRC).Methods The second-line chemotherapy therapies includes RALOX/RALIRI/ CAPOX/CAPIRI/FOLFOX/FOLFIRI in mCRC from the perspective of China health care system.Effectiveness data were extracted from randomized clinical trials.Costs were obtained from medical insurance database and inpatient care data.The robustness of the result was evaluated by one-way sensitivity analyses.Results CAPIRI was not cost-effective compared with CAPOX.RALOX was compared to CAPOX with an ICER estimated at￥26,384per overal survival year.RALOX was cost-effective compared to CAPOX with an ICER at￥26,384per overal survival year,which was smaler than the cost of per year of life saved.FOLFOX/RALIRI/FOLFIRI were not costeffe- ctive compared with RALOX.Conclusion RALOX is the most cost-effective second line therapy for mCRC,and thus RALOX is the optimal option in the treatment of mCRC.关键词
雷替曲塞/二线化疗/转移性结直肠癌/成本-效果分析Key words
Raltitrexed/Metastatic colorectal cancer/Chemotherapy therapy/Cost-Effectivness Analysis分类
医药卫生引用本文复制引用
边申溦,刘跃华,刘国恩..转移性结直肠癌二线化疗方案的成本-效果分析[J].中国药物经济学,2016,(2):7-10,4.
